Biological markers of disease activity in inflammatory bowel diseases.

IF 1.7 Q3 GASTROENTEROLOGY & HEPATOLOGY Przegla̜d Gastroenterologiczny Pub Date : 2023-01-01 DOI:10.5114/pg.2023.129412

Edyta Szymanska, Sylwia Szymanska, Maciej Dadalski, Jaroslaw Kierkus

{"title":"Biological markers of disease activity in inflammatory bowel diseases.","authors":"Edyta Szymanska, Sylwia Szymanska, Maciej Dadalski, Jaroslaw Kierkus","doi":"10.5114/pg.2023.129412","DOIUrl":null,"url":null,"abstract":"<p><p>Inflammatory bowel diseases (IBD) are chronic intestinal conditions of multifactorial aetiology including genetic susceptibility, immunological impairment, dysbiosis, and environmental factors. The diagnosis is based on both clinical and endoscopic features, wherein histopathological evaluation remains a gold diagnostic standard. However, fast, reliable, and non-invasive biological markers have been used for years for diagnosis as well as for disease activity monitoring. Currently, commonly used faecal calprotectin is the only biomarker approved and recommended by the European Crohn's and Colitis Organization (ECCO). Nonetheless, other biological markers discriminating between functional and organic bowel conditions have been widely studied. Therefore, the aim of this manuscript was to review new potential biomarkers of inflammation in IBD. The aim of this study was to review currently available biomarkers of intestinal inflammation and increased gut permeability in IBD.</p>","PeriodicalId":20719,"journal":{"name":"Przegla̜d Gastroenterologiczny","volume":"18 2","pages":"141-147"},"PeriodicalIF":1.7000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/dd/5e/PG-18-51066.PMC10395055.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Przegla̜d Gastroenterologiczny","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5114/pg.2023.129412","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Inflammatory bowel diseases (IBD) are chronic intestinal conditions of multifactorial aetiology including genetic susceptibility, immunological impairment, dysbiosis, and environmental factors. The diagnosis is based on both clinical and endoscopic features, wherein histopathological evaluation remains a gold diagnostic standard. However, fast, reliable, and non-invasive biological markers have been used for years for diagnosis as well as for disease activity monitoring. Currently, commonly used faecal calprotectin is the only biomarker approved and recommended by the European Crohn's and Colitis Organization (ECCO). Nonetheless, other biological markers discriminating between functional and organic bowel conditions have been widely studied. Therefore, the aim of this manuscript was to review new potential biomarkers of inflammation in IBD. The aim of this study was to review currently available biomarkers of intestinal inflammation and increased gut permeability in IBD.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

炎症性肠病疾病活动性的生物学标志物。

炎症性肠病(IBD)是一种多因素的慢性肠道疾病，病因包括遗传易感性、免疫功能障碍、生态失调和环境因素。诊断是基于临床和内镜特征，其中组织病理学评估仍然是金诊断标准。然而，快速、可靠和无创的生物标记物多年来一直用于诊断和疾病活动监测。目前，常用的粪钙保护蛋白是欧洲克罗恩病和结肠炎组织(ECCO)批准和推荐的唯一生物标志物。尽管如此，其他区分功能性和器质性肠道疾病的生物标志物已被广泛研究。因此，本文的目的是回顾IBD中新的潜在炎症生物标志物。本研究的目的是回顾目前可用的IBD肠道炎症和肠道通透性增加的生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Przegla̜d Gastroenterologiczny GASTROENTEROLOGY & HEPATOLOGY-

CiteScore

2.20

自引率

7.70%

发文量

审稿时长

6-12 weeks

期刊介绍： Gastroenterology Review is a journal published each 2 months, aimed at gastroenterologists and general practitioners. Published under the patronage of Consultant in Gastroenterology and Polish Pancreatic Club.